甲基2-烯丙基-3-羟基苯甲酸酯 | 79950-39-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 甲基2-烯丙基-3-羟基苯甲酸酯
• 英文名称: methyl 2-allyl-3-hydroxybenzoate
• 英文别名: methyl 3-hydroxy-2-prop-2-enylbenzoate
• CAS: 79950-39-3
• 化学式: C₁₁H₁₂O₃
• 分子量: 192.214
• InChiKey: VSTQTFKFAWHJON-UHFFFAOYSA-N

物化性质

• 沸点：
  325.9±30.0 °C(Predicted)
• 密度：
  1.129±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  甲基2-烯丙基-3-羟基苯甲酸酯 在 二甲基硫 、 磷酸 、 臭氧 作用下， 反应 0.92h， 生成 苯并呋喃-4-羧酸甲酯; 4-苯并呋喃羧酸甲酯
  参考文献：
  名称：

  Aminoalkylindoles: Structure-Activity Relationships of Novel Cannabinoid Mimetics

  摘要：

  Aminoalkylindoles (AAIs) are a novel series of cannabinoid receptor ligands. In this report we disclose the structural features of AAIs which are important for binding to this receptor as measured by inhibition of binding of [H-3]Win 55212-2 (5). Functional activity in the mouse vas deferens is also noted and used to distinguish agonists from potential antagonists. The key structural features for potent cannabinoid activity in this series are a bicyclic (naphthyl) substituent at the 3-position, a small (II) substituent at the 2-position, and an aminoethyl (morpholinoethyl) substituent at the 1-position. A 6-bromo analog, Win 54461 (31), has been identified as a potential cannabinoid receptor antagonist. Modeling experiments were done to develop a pharmacophore and also to compare AAI structures with those of classical cannabinoids. The fact that the cannabinoid AAIs arose out of work on a series of cyclooxygenase inhibitors makes sense now that an endogenous cannabinoid ligand has been identified which is a derivative of arachidonic acid. Because of their unique structures and physical properties, AAIs provide useful tools to study the structure and function of the cannabinoid receptor(s).

  DOI：

  10.1021/jm00016a013
• 作为产物：
  描述：

  methyl 3-(allyloxy)benzoate 以41的产率得到甲基2-烯丙基-3-羟基苯甲酸酯
  参考文献：
  名称：

  [EN] BENZODIOXOLE, BENZOFURAN, DIHYDROBENZOFURAN, AND BENZODIOXANE MELATONERGIC AGENTS
  [FR] LES BENZODIOXOLE, BENZOFURAN, DIHYDROBENZOFURAN, ET BENZODIOXANE: DES AGENTS MELATONERGIQUES

  摘要：

  这段话的中文翻译如下： (EN) Novel derivatives of benzodioxole, benzofuran, 2,3-dihydrobenzofuran, and benzodioxane are useful as melatonergic agents. (中) 新型苯并二氧杂环、苯并呋喃、2,3-二氢苯并呋喃和苯并二氧杂环的衍生物可作为褪黑素能药物使用。 (FR) La présente invention concerne de nouveaux dérivés des benzodioxole, benzofuran, 2,3-dihydrobenzofuran, et benzodioxane qui conviennent particulièrement comme agents mélatonergiques. (中) 本发明涉及苯并二氧杂环、苯并呋喃、2,3-二氢苯并呋喃和苯并二氧杂环的新型衍生物，特别适用于作为褪黑素能药物。

  公开号：

  WO1998025606A1

文献信息

• THIAZOLIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS
  申请人：Aissaoui Hamed

  公开号：US20100113531A1

  公开（公告）日：2010-05-06

  The invention relates to novel thiazolidine derivatives of the formula (I) wherein A and R 1 are as described in the description and their use as medicaments, especially as orexin receptor antagonists.

  本发明涉及式(I)的新噻唑啉衍生物，其中A和R1如描述中所述，以及它们作为药物的使用，尤其是作为食欲素受体拮抗剂的使用。
• Novel 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof
  申请人：Molino F. Bruce

  公开号：US20060111385A1

  公开（公告）日：2006-05-25

  The present invention relates to a method of treating disorders including cognition impairment, generalized anxiety disorder, acute stress disorder, social phobia, simple phobias, pre-menstrual dysphoric disorder, social anxiety disorder, major depressive disorder, eating disorders, obesity, anorexia nervosa, bulimia nervosa, binge eating disorder, substance abuse disorders, chemical dependencies, nicotine addiction, cocaine addiction, alcohol addiction, amphetamine addiction, Lesch-Nyhan syndrome, neurodegenerative diseases, late luteal phase syndrome, narcolepsy, psychiatric symptoms anger, rejection sensitivity, movement disorders, extrapyramidal syndrome, Tic disorder, restless leg syndrome, tardive dyskinesia, sleep related eating disorder, night eating syndrome, stress urinary incontinence, migraine, neuropathic pain, diabetic neuropathy, fibromyalgia syndrome, chronic fatigue syndrome, sexual dysfunction, premature ejaculation, and male impotence. This method involves administering to a patient in need of such treatment a therapeutically effective amount of a disclosed compound. Such compounds are 4-phenyl substituted tetrahydroisoquinolines having the Formula IA, IB, IIA, IIB, IIIA or IIIC as set forth herein.

  本发明涉及一种治疗包括认知障碍、广泛性焦虑障碍、急性应激障碍、社交恐惧症、简单恐惧症、经前期情绪性失调障碍、社交焦虑障碍、重度抑郁障碍、进食障碍、肥胖症、厌食症、暴食症、物质滥用障碍、化学依赖、尼古丁成瘾、可卡因成瘾、酒精成瘾、安非他命成瘾、莱什-尼汉综合征、神经退行性疾病、月经后期综合征、嗜睡症、精神症状愤怒、拒绝敏感性、运动障碍、锥体外症候群、抽动障碍、不安腿综合征、迟发性运动障碍、与睡眠相关的进食障碍、夜间进食综合征、压力性尿失禁、偏头痛、神经痛、糖尿病性神经病变、纤维肌痛综合征、慢性疲劳综合征、性功能障碍、早泄和男性阳痿等多种疾病的方法。该方法涉及向需要此类治疗的患者施用所述化合物的治疗有效量。这些化合物是具有以下IA、IB、IIA、IIB、IIIA或IIIC式的4-苯基取代四氢异喹啉。
• Design, synthesis and pharmacology of 1,1-bistrifluoromethylcarbinol derivatives as liver X receptor β-selective agonists
  作者：Minoru Koura、Takayuki Matsuda、Ayumu Okuda、Yuichiro Watanabe、Yuki Yamaguchi、Sayaka Kurobuchi、Yuuki Matsumoto、Kimiyuki Shibuya

  DOI：10.1016/j.bmcl.2015.04.080

  日期：2015.7

  A novel series of 1,3-bistrifluoromethylcarbinol derivatives that act as liver X receptor (LXR) β-selective agonists was discovered. Structure–activity relationship studies led to the identification of molecule 62, which was more effective (Emax) and selective toward LXRβ than T0901317 and GW3965. Furthermore, 62 decreased LDL-C without elevating the plasma TG level and significantly suppressed the

  发现了一系列作为肝 X 受体 (LXR) β-选择性激动剂的新型 1,3-双三氟甲基甲醇衍生物。结构-活性关系研究导致分子62的鉴定，它比 T0901317 和 GW3965 对 LXRβ更有效 ( E max ) 和选择性。此外，在 Bio F 1中， 62降低了 LDL-C 而没有提高血浆 TG 水平，并显着抑制了主动脉弓中的脂质积聚区域B 仓鼠喂食高脂肪和高胆固醇的饮食。我们证明了我们的 LXRβ 激动剂可能用作降血脂和抗动脉粥样硬化剂。在这份手稿中，我们报告了 1,3-双三氟甲基甲醇衍生物的设计、合成和药理学。
• [EN] POLYMORPH FORMS OF (S)-2-((4-BENZOFURANYL)CARBONYLAMINOMETHYL)-1-((4-(2-METHYL-5-(4-FLUOROPHENYL)THIAZOLYL)CARBONYL)PIPERIDINE<br/>[FR] FORMES POLYMORPHES DE (S)-2-((4-BENZOFURANYL)CARBONYLAMINOMÉTHYL)-1-((4-(2-MÉTHYL-5-(4-FLUOROPHÉNYL)THIAZOLYL)CARBONYL)PIPÉRIDINE
  申请人：GLAXO GROUP LTD

  公开号：WO2009034133A1

  公开（公告）日：2009-03-19

  New crystalline forms of (S)-2-((4-benzofuranyl)carbonylamino methyl)-1-((4-(2-methyl-5-(4-fluorophenyl))thiazolyl)carbonyl)piperidine, methods for their preparation and use in medicine as orexin receptor antagonist.

  (S)-2-((4-苯并呋喃基)羰基氨甲基)-1-((4-(2-甲基-5-(4-氟苯基)噻唑基)羰基)哌啶的新结晶形式，其制备方法以及作为促觉醒素受体拮抗剂在医学上的用途。
• Quinazoline derivatives
  申请人：——

  公开号：US20040044015A1

  公开（公告）日：2004-03-04

  The invention concerns quinazoline derivatives of Formula (I) wherein each of m, R 1 , n, R 2 and R 3 have any of the meanings defined in the description; process for the preparation, pharmaceutical compositions them and their use in the manufacture of a medicament for use as an anti-invasive agent in the containment and/or treatment of solid tumour disease.

  这项发明涉及式（I）的喹唑啉衍生物，其中m、R1、n、R2和R3中的每一个具有描述中定义的任意含义；制备过程，药物组合物及其在制备用作抗侵袭剂的药物中的使用，用于包含和/或治疗固体肿瘤疾病。